# A commons for leftover trial biospecimens with standard access for approved research

Source: https://onco.cc/ideas/idea-fund-trial-biospecimen-commons/  
OnCo record `idea-fund-trial-biospecimen-commons` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Blood and tissue samples collected in cancer trials are the best material for validating new tests, but most sit unused under contracts that make access impossible. A commons would make them available for approved research.

## Summary

Sponsors and academic trial groups deposit or catalogue residual biospecimens from completed trials (with linked clinical outcomes) in a federated commons with a single access committee, standard consent language for future trials that permits secondary research, and cost-recovery pricing. Access priority goes to biomarker validation studies and to negative-trial samples that can explain why drugs failed. The NCI's cooperative group banks and the EORTC's SPECTA show the model at small scale; the change is universal deposit obligations and one door to knock on.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: A biospecimen commons increases the number of biomarker validation studies using randomised-trial samples by at least threefold within three years and reduces the median time from request to sample receipt to under six months.
- Rationale: Prospective-retrospective validation on trial samples is the recognised gold standard for predictive biomarkers, and the main obstacle reported by investigators is access, not science. Standard consent and single access committees have worked for national biobanks such as UK Biobank.
- Proposed test: Pilot deposit from five completed trials with a standard access process; measure requests, approvals, time to receipt and studies published over two years.
- Maturity: early-clinical
- Actor: data

## Sources

- UK Biobank: https://www.ukbiobank.ac.uk/

## Connected records

- ideas: [A fund for prospective validation of academic biomarkers and companion diagnostics](https://onco.cc/ideas/idea-fund-biomarker-validation-fund/), [A single oncology trial data trust with mandatory deposit within eighteen months](https://onco.cc/ideas/idea-fund-trial-data-trust/), [Patient-held portable consent for reusing samples and data across studies](https://onco.cc/ideas/idea-fund-portable-patient-consent/)
- technologies: [Companion diagnostics](https://onco.cc/technologies/companion-diagnostic/), [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Proteomics & phosphoproteomics](https://onco.cc/technologies/proteomics/)
- bottlenecks: [Biomarkers are not validated or standardised](https://onco.cc/bottlenecks/b-biomarker-validation/), [Secrecy and intellectual property block collaboration](https://onco.cc/bottlenecks/b-ip-collaboration/)

---
JSON: https://onco.cc/api/v1/entities/idea-fund-trial-biospecimen-commons.json